Intra-Cellular Therapies (BSP:I2TC34) Beginning Cash Position : R$745 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Intra-Cellular Therapies Beginning Cash Position?

Intra-Cellular Therapies's Beginning Cash Position for the quarter that ended in Mar. 2024 was R$745 Mil.

Intra-Cellular Therapies's quarterly Beginning Cash Position declined from Sep. 2023 (R$711 Mil) to Dec. 2023 (R$496 Mil) but then increased from Dec. 2023 (R$496 Mil) to Mar. 2024 (R$745 Mil).

Intra-Cellular Therapies's annual Beginning Cash Position increased from Dec. 2021 (R$347 Mil) to Dec. 2022 (R$492 Mil) and increased from Dec. 2022 (R$492 Mil) to Dec. 2023 (R$737 Mil).

Intra-Cellular Therapies Beginning Cash Position Historical Data

The historical data trend for Intra-Cellular Therapies's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intra-Cellular Therapies Beginning Cash Position Chart

Intra-Cellular Therapies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

225.53

553.76

347.47

491.84

736.76

Intra-Cellular Therapies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															783.19	376.05	711.21	495.62	744.57

Intra-Cellular Therapies Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Intra-Cellular Therapies Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Intra-Cellular Therapies (BSP:I2TC34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (BSP:I2TC34) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

ITCI:USA ITCI:Mexico 23I:Germany

Address

430 East 29th Street, New York, NY, USA, 10016

Website

https://www.intracellulartherapies.com

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Intra-Cellular Therapies (BSP:I2TC34) Headlines

No Headlines